Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease.

II. Identify subgroups of patients with Cushing's disease who differ in the presence and severity of the depressive syndrome, and uncover HPA axis dysregulation differences among them using corticotropin-releasing hormone, metyrapone, and dexamethasone challenge testing.


Clinical Trial Description

PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol, and urinary cortisol. Peptide and steroid assays are performed, alone and in response to corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep electroencephalograms at baseline and 1 year following treatment.

A weight maintenance diet is prescribed for all patients. ;


Study Design

Primary Purpose: Screening


Related Conditions & MeSH terms


NCT number NCT00004334
Study type Observational
Source National Center for Research Resources (NCRR)
Contact
Status Recruiting
Phase N/A
Start date July 1994

See also
  Status Clinical Trial Phase
Completed NCT02468193 - Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Phase 2
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Completed NCT00006278 - Study of Cushing's Syndrome Not Related to ACTH Production N/A
Completed NCT00361777 - Diagnostic Performance of Screening Tests for Cushing s Syndrome
Active, not recruiting NCT03606408 - Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 Phase 2
Completed NCT02663609 - Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Recruiting NCT01504555 - Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Phase 3
Active, not recruiting NCT00004343 - Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome N/A
Completed NCT02922257 - Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Terminated NCT00422201 - Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Phase 2
Completed NCT00001180 - Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency N/A
Completed NCT02804750 - Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Phase 2
Completed NCT00936741 - An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Phase 3
Completed NCT03817840 - Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
Completed NCT01959711 - Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Phase 4
Completed NCT05633953 - Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Completed NCT02889224 - In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man N/A
Terminated NCT00796783 - A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia N/A
Recruiting NCT02019706 - Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome Phase 2